Si-Yan Chen

Dr. Si-Yan Chen


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Interactive Journal of Medical Research
Verified
Journal Article
Open access
JLJia-yuan Luo
Jia-yuan Luo
YDYu-Long Deng
Yu-Long Deng
SLShang-Yi Lu
Shang-Yi Lu
SCSi-Yan Chen
Si-Yan Chen
RHRongquan He
Rongquan He
WPWei Peng
Wei Peng
Background: Ferroptosis, as a novel modality of cell death, holds significant potential in elucidating the pathogenesis and advancing therapeutic strategies for breast cancer. Objective: This study aims to comprehensively analyze current ferroptosis research and future trends, guiding breast cancer research advancements and innovative treatment strategies. Methods: This research used the R package Bibliometrix (Department of Economic and Statistical Sciences at the University of Naples Federico II), VOSviewer (Centre for Science and Technology Studies at Leiden University), and CiteSpace (Drexel University’s College of Information Science and Technology), to conduct a bibliometric analysis of 387 papers on breast cancer and ferroptosis from the Web of Science Core Collection. The analysis covers authors, institutions, journals, countries or regions, publication volumes, citations, and keywords. Results: The number of publications related to this field has surged annually, with China and the United States collaborating closely and leading in output. Sun Yat-sen University stands out among the institutions, while the journal Frontiers in Oncology and the author Efferth T contribute significantly to the field. Highly cited papers within the domain primarily focus on the induction of ferroptosis, protein regulation, and comparisons with other modes of cell death, providing a foundation for breast cancer treatment. Keyword analysis highlights the maturity of glutathione peroxidase 4-related research, with breast cancer subtypes emerging as motor themes and the tumor microenvironment, immunotherapy, and prognostic models identified as basic themes. Furthermore, the application of nanoparticles serves as an additional complement to the basic themes. Conclusions: The current research status in the field of ferroptosis and breast cancer primarily focuses on the exploration of relevant theoretical mechanisms, whereas future trends and mechanisms emphasize the investigation of therapeutic strategies, particularly the clinical application of immunotherapy related to the tumor microenvironment. Nanotherapy has demonstrated significant clinical potential in this domain. Future research directions should deepen the exploration in this field and accelerate the clinical translation of research findings to provide new insights and directions for the innovation and development of breast cancer treatment strategies.

17 March 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
LWLei Wang
Lei Wang
SCSi-Yan Chen
Si-Yan Chen
JLJun-Li Li
Jun-Li Li
JDJian Dai
Jian Dai
DQDi-Yuan Qin
Di-Yuan Qin
GCGang Chen
Gang Chen
Sleeping disorders negatively affect cancer patient management, quality of life, and recovery. Immunotherapy, a rising cancer treatment, shows potential to improve sleep quality by reducing inflammation. This study analyzed 255 publications (2000-2024) from the Web of Science Core Collection using bibliometric methods. The US and China dominate research output, with The Mayo Clinic as a key contributor. Core topics are "immunotherapy," "quality of life," and "antibodies." Emerging keywords like "cancer," "encephalitis," and "depression" highlight a shift toward clinical psychology in treating tumors and rare diseases. It is noteworthy that with the rapid expansion of immunotherapy in cancer treatment, clinical trials have shown that it can improve sleep quality in cancer patients by reducing inflammation. As its application in cancer treatment expands, immunotherapy's potential for treating sleep disorders is promising. Future development is expected to improve sleep quality and address clinical issues, offering broad prospects for patient outcomes.

9 September 2024 in JMIR Preprints
Verified
Preprint
Open access
JLJia-yuan Luo
Jia-yuan Luo
YDYu-Long Deng
Yu-Long Deng
SLShang-Yi Lu
Shang-Yi Lu
SCSi-Yan Chen
Si-Yan Chen
RHRongquan He
Rongquan He
WPWei Peng
Wei Peng
BACKGROUND Ferroptosis, as a novel modality of cell death, holds significant potential in elucidating the pathogenesis and advancing therapeutic strategies for breast cancer. OBJECTIVE This study aims to comprehensively analyze current ferroptosis research and future trends, guiding breast cancer research advancements and innovative treatment strategies. METHODS This research used the R package Bibliometrix (Department of Economic and Statistical Sciences at the University of Naples Federico II), VOSviewer (Centre for Science and Technology Studies at Leiden University), and CiteSpace (Drexel University’s College of Information Science and Technology), to conduct a bibliometric analysis of 387 papers on breast cancer and ferroptosis from the Web of Science Core Collection. The analysis covers authors, institutions, journals, countries or regions, publication volumes, citations, and keywords. RESULTS The number of publications related to this field has surged annually, with China and the United States collaborating closely and leading in output. Sun Yat-sen University stands out among the institutions, while the journal Frontiers in Oncology and the author Efferth T contribute significantly to the field. Highly cited papers within the domain primarily focus on the induction of ferroptosis, protein regulation, and comparisons with other modes of cell death, providing a foundation for breast cancer treatment. Keyword analysis highlights the maturity of glutathione peroxidase 4-related research, with breast cancer subtypes emerging as motor themes and the tumor microenvironment, immunotherapy, and prognostic models identified as basic themes. Furthermore, the application of nanoparticles serves as an additional complement to the basic themes. CONCLUSIONS The current research status in the field of ferroptosis and breast cancer primarily focuses on the exploration of relevant theoretical mechanisms, whereas future trends and mechanisms emphasize the investigation of therapeutic strategies, particularly the clinical application of immunotherapy related to the tumor microenvironment. Nanotherapy has demonstrated significant clinical potential in this domain. Future research directions should deepen the exploration in this field and accelerate the clinical translation of research findings to provide new insights and directions for the innovation and development of breast cancer treatment strategies.

22 August 2026 in Hereditas
Verified
Journal Article
Open access
PDF file
KWKe-Jun Wu
Ke-Jun Wu
LWLei Wang
Lei Wang
YZYan-Ting Zhan
Yan-Ting Zhan
YTYu-Lu Tang
Yu-Lu Tang
MLMing-Jie Li
Ming-Jie Li
SCSi-Yan Chen
Si-Yan Chen
Background: Cholangiocarcinoma (CHOL) is a highly heterogeneous and aggressive malignancy that is frequently diagnosed at an advanced stage because of the lack of early biomarkers, resulting in a poor prognosis. Although ANAPC1 overexpression has been reported in other cancers, its role and regulatory mechanisms in CHOL remain insufficiently characterized. Objectives: To characterize ANAPC1 expression in CHOL, identify candidate upstream transcriptional regulators, and elucidate the associated functional programs and pathways. Methods: Multi-omics profiling was integrated with in-house immunohistochemical validation. Differential expression analyses, CRISPR-based functional screening, transcription-factor prioritization, ChIP-seq with epigenomic annotation, gene set enrichment analysis, spatial transcriptomics, and single-cell RNA-seq were conducted to investigate ANAPC1-associated regulatory mechanisms in CHOL.Structural modeling of predicted TEAD4–DNA complexes was additionally performed to assess the structural compatibility between TEAD4 and candidate ANAPC1 promoter motifs. Results: ANAPC1 was significantly overexpressed in CHOL at both the transcriptomic level (436 CHOL vs. 213 non-CHOL samples) and the protein level (66 CHOL vs. 99 non-CHOL tissues), with spatial enrichment in cholangiocytes. Public CRISPR dependency screening indicated that ANAPC1 loss was associated with reduced cellular fitness in several CHOL cell lines, including HUCCT1. Integrative analyses identified TEAD4 as a candidate upstream regulator of ANAPC1, and TEAD4 was upregulated in CHOL. Public ChIP-seq and epigenomic datasets across multiple cell lines, including HUCCT1, HepG2, BE2-C, and MDA-MB-231, suggested TEAD4 occupancy at the ANAPC1 locus, together with active chromatin features such as H3K27ac signals near the promoter region. Across several bulk transcriptomic datasets, TEAD4 and ANAPC1 showed positive expression associations of varying magnitude, whereas spatial transcriptomics indicated partially overlapping regional enrichment within malignant areas.Protein–DNA complex modeling of a predicted candidate TEAD4–ANAPC1 promoter DNA complex yielded an ipTM score of 0.71 and a pTM score of 0.62 for the top-ranked candidate promoter motif. GSEA identified positive enrichment of proliferation- and RNA-processing-related pathways and negative enrichment of several immune-related pathways within the ANAPC1-correlated transcriptomic profile. Single-cell analysis further localized ANAPC1 expression mainly to cholangiocytes and identified a statistically significant but extremely weak cell-level correlation with TEAD4. Conclusions: These findings support the hypothesis of a putative TEAD4–ANAPC1 regulatory relationship in CHOL based on integrative epigenomic, transcriptomic, spatial, and structural analyses. Direct experimental validation is required to determine whether TEAD4 functionally regulates ANAPC1 transcription in cholangiocarcinoma.